Disease Awareness Information: The Xiaflex Dupuytren's Dilemma
This article was originally published in RPM Report
Executive Summary
Is FDA trying effectively to ban the practice of providing disease awareness information in promotoional materials? A recent letter to Auxilium on promotional materials for the company's drug for Dupuytren Disease (Xiaflex) suggests FDA is still looking closely at how companies describe disease states compared to a product's labeled indications.